ZHONGZHU HEALTHCARE HOLDING(600568)

Search documents
ST中珠:董事会同意聘任刘会平先生为公司副总裁
Mei Ri Jing Ji Xin Wen· 2025-08-15 08:19
ST中珠(SH 600568,收盘价:1.88元)8月15日晚间发布公告称,经公司总裁麻华先生提名,董事会同 意聘任刘会平先生为公司副总裁。 2024年1至12月份,ST中珠的营业收入构成为:医院收入占比55.6%,房地产项目占比25.33%,医药行 业占比8.94%,医疗器械占比4.74%,中心合作占比4.17%。 (文章来源:每日经济新闻) ...
ST中珠(600568) - 中珠医疗控股股份有限关于下属公司涉及诉讼的公告
2025-08-15 08:15
证券代码:600568 证券简称:ST 中珠 公告编号:2025-035 号 重要内容提示: 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")下属中珠 俊天(北京)医疗科技有限公司(以下简称"中珠俊天")于 2025 年 8 月 15 日 收到北京市第二中级人民法院(以下简称"北京二中院")出具的受理案件通知 书((2025)京 02 民初 1453 号),因中珠俊天与北京弘洁润众咨询有限公司(原 弘洁实业控股集团有限公司,以下简称"弘洁润众")房屋租赁合同纠纷一案, 北京二中院已立案。具体内容如下: 中珠医疗控股股份有限公司 关于下属公司涉及诉讼的公告 一、本次诉讼的基本情况 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 1、原告:中珠俊天(北京)医疗科技有限公司 住所地:北京市丰台区花乡高立庄 615-1 号 2、被告:北京弘洁润众咨询有限公司 住所地:北京市丰台区花乡高立庄 616 号新华国际中心 C 座 3 层 330 室 3、受理法院:北京市第二中级人民法院 案件所处的诉讼阶段:已立案,尚未开庭 ...
ST中珠(600568) - 中珠医疗控股股份有限公司关于聘任公司高级管理人员的公告
2025-08-15 08:15
经公司总裁麻华先生提名,董事会同意聘任刘会平先生为公司副总裁,任 期自公司第十届董事会审议通过之日起至公司第十届董事会换届完成之日止。 公司提名委员会认为:经审查,本次提名的副总裁候选人刘会平先生符合 相关法律法规规定担任上市公司高级管理人员的条件,不存在《公司法》第一 百七十八条规定的情况,不存在被中国证监会采取不得担任上市公司董事、监 事和高级管理人员的市场禁入措施期限未届满的情况,不存在被上海证券交易 所公开认定为不适合担任上市公司董事、监事和高级管理人员期限尚未届满的 情况。本次提名的候选人的职业、学历、职称、工作履历等均符合高级管理人 员任职资格和任职条件。 刘会平先生简历详见附件。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")于 2025 年 8 月 15 日召开第十届董事会第八次会议,审议通过聘任公司副总裁的议案, 现将具体情况公告如下: 一、聘任公司副总裁的情况 证券代码:600568 证券简称:ST 中珠 公告编号:2025-034 号 中珠医疗控 ...
中珠医疗控股股份有限公司关于公司涉及诉讼的进展公告
Shang Hai Zheng Quan Bao· 2025-08-14 18:59
Core Viewpoint - The company, Zhongzhu Medical Holdings Co., Ltd., has reached a settlement in multiple lawsuits involving significant amounts owed by various defendants, primarily Zhongzhu Group, with repayment obligations established by the court [2][10]. Group 1: Lawsuit Details - Lawsuit amounts include: - Lawsuit One: 56,717,917.98 CNY [5] - Lawsuit Two: 570,000 CNY [4] - Lawsuit Three: 29,644,488.22 CNY [5] - Lawsuit Four: 139,640,041.46 CNY [7] - Lawsuit Five: 4,812,930.87 CNY [8] - Lawsuit Six: 75,976,378.75 CNY [9] - The company has acted as the plaintiff in these cases, seeking to recover debts owed by the defendants [4][10]. Group 2: Settlement Agreements - The defendants, primarily Zhongzhu Group, have committed to repay the owed amounts by August 25, 2025, with a specified order of payment prioritizing costs, interest, and then principal [5][8][9]. - If the defendants fail to meet their repayment obligations, the company reserves the right to seek enforcement through the court [5][8][9]. Group 3: Financial Impact - The company currently cannot confirm the impact of these settlements on its profits for the current or future periods, as the repayment obligations are still pending [2][10]. - The company will continue to disclose updates regarding the repayment progress in accordance with regulatory requirements [10].
ST中珠: 中珠医疗控股股份有限关于公司涉及诉讼的进展公告
Zheng Quan Zhi Xing· 2025-08-14 11:11
Core Viewpoint - The company, Zhongzhu Medical Holdings Co., Ltd., has reached a settlement in multiple lawsuits involving contract disputes with various parties, including Zhongzhu Group and other real estate companies, with specific repayment obligations outlined in the civil mediation documents [1][2][3][4][5][6]. Summary by Relevant Sections Litigation Overview - The company filed lawsuits against Zhongzhu Group and other defendants due to unpaid debts totaling approximately 56.43 million yuan for the first lawsuit, with additional amounts for subsequent lawsuits [2][3][4][5][6]. Settlement Details - The mediation agreements specify repayment amounts and timelines, including: - Lawsuit 1: 56,717,917.98 yuan (principal: 51 million yuan, interest: 5,717,917.98 yuan) [1][2]. - Lawsuit 2: 570,000 yuan in interest [2][3]. - Lawsuit 3: 29,644,488.22 yuan (principal: 3,952.05 yuan, interest: 26,790,536.17 yuan) [3][4]. - Lawsuit 4: 139,640,041.46 yuan (principal: 122,958,200 yuan, interest: 16,681,841.46 yuan) [4]. - Lawsuit 5: 4,812,930.53 yuan (principal: 1,347,773.26 yuan, interest: 3,465,157.27 yuan) [5]. - Lawsuit 6: 75,745,666.67 yuan (principal: 66,900,000 yuan, interest: 9,076,378.75 yuan) [5][6]. Impact on Financials - The company cannot currently determine the impact of these settlements on its profits for the current or future periods, as the defendants are required to fulfill their repayment obligations [2][6]. Disclosure of Other Legal Matters - The company confirms that there are no undisclosed lawsuits or arbitration matters pending [7].
ST中珠(600568) - 中珠医疗控股股份有限关于公司涉及诉讼的进展公告
2025-08-14 11:00
证券代码:600568 证券简称:ST 中珠 公告编号:2025-033 号 中珠医疗控股股份有限公司 关于公司涉及诉讼的进展公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 诉讼二:570,000 元; 诉讼三:29,644,466.16 元; 诉讼四:139,216,006.45 元 诉讼五:4,808,282.59 元 诉讼六:75,745,666.67 元 是否会对上市公司损益产生负面影响:本次案件均已和解,相关被告方 尚需履行还款义务,暂时无法确认对本公司本期利润或期后利润的影响。 公司将根据相关方还款的进展情况及时履行相应的信息披露义务。 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")于 2025 年 8 月 14 日收到珠海市香洲区人民法院(以下简称"香洲区法院")出具的《广 东省珠海市香洲区人民法院民事调解书》六份((2025)粤 0402 民初 3403 号、 (2025)粤 0402 民初 3402 号、(2025)粤 0402 民初 4728 号、(2025)粤 ...
医疗服务板块8月13日涨4.02%,创新医疗领涨,主力资金净流入19.62亿元
Zheng Xing Xing Ye Ri Bao· 2025-08-13 08:41
Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]
A股平均股价12.63元 36股股价不足2元
Zheng Quan Shi Bao Wang· 2025-08-12 09:40
Core Points - The average stock price of A-shares is 12.63 yuan, with 36 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.08 yuan [1] - Among the low-priced stocks, 12 are ST stocks, accounting for 33.33% of the total [1] - The Shanghai Composite Index closed at 3665.92 points as of August 12 [1] Low-Priced Stocks Summary - The lowest priced stock is *ST Suwu at 1.08 yuan, followed by *ST Jinke at 1.41 yuan and Rongsheng Development at 1.43 yuan [1] - In terms of market performance, 15 of the low-priced stocks increased in price, with ST Zhongzhu rising by 5.03%, *ST Tianmao by 2.63%, and *ST Jinglan by 1.75% [1] - Conversely, 12 stocks decreased in price, with Shandong Steel dropping by 1.29%, Chongqing Steel by 1.28%, and *ST Jinke by 0.70% [1] Detailed Low-Priced Stocks Table - The table includes various low-priced stocks with their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [2] - Notable stocks include ST Zhongzhu at 1.88 yuan with a 5.03% increase, and *ST Xingguang at 1.96 yuan with a 1.03% increase [2]
医疗服务板块8月12日跌0.12%,海特生物领跌,主力资金净流出3.81亿元
Zheng Xing Xing Ye Ri Bao· 2025-08-12 08:22
| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 50.48 | -8.67% | 15.85万 | 8.11亿 | | 000504 | *ST生物 | 11.91 | -5.02% | 3.61万 | 4301.65万 | | 688710 | 益诺思 | 42.19 | -3.01% | 1.48万 | 6274.17万 | | 688222 | 成都先导 | 22.28 | -2.88% | 1 20.73万 | 4.60亿 | | 301509 | 金凯生松 | 38.46 | -2.83% | 5.59万 | 2.15亿 | | 688238 | 和元生物 | 7.61 | -2.56% | 13.40万 | 1.02亿 | | 301201 | 诚达药业 | 28.83 | -2.47% | 5.98万 | 1.73亿 | | 300149 | 香督医药 | 12.63 | -2.40% | 36.15万 | 4.58亿 | | 688621 | 阳光 ...
ST中珠:副总裁曾钰成因个人原因辞职
Xin Lang Cai Jing· 2025-08-11 10:49
Core Viewpoint - The company announced the resignation of its Vice President, Zeng Yucheng, due to personal reasons, effective immediately upon the delivery of his written resignation to the board [1] Group 1 - The resignation of Zeng Yucheng means he will no longer hold any position within the company after his departure [1]